logo
Is there a new global health threat? Fungal superbugs spread panic with climate change expanding its reach

Is there a new global health threat? Fungal superbugs spread panic with climate change expanding its reach

Time of India07-05-2025

5
5
Next Stay
Playback speed
1x Normal
Back
0.25x
0.5x
1x Normal
1.5x
2x
5
5
/
Skip
Ads by
Another dangerous fungus causes lung issues
WHO lists 19 fungal species as urgent priorities
Live Events
Climate change could exacerbate the spread
Urgent need for antifungal innovation
FAQs:
A new global health threat is emerging—drug-resistant fungal infections . These microscopic fungal spores like Coccidioides , responsible for valley fever , are infecting people who inhale them from air or soil, even in their own backyards.Torrence Irvin from California became critically ill after he unknowingly inhaled the spores. Doctors took nearly a year to correctly diagnose him. However, by that time, he had lost a significant amount of weight and nearly died.As per a CNN report, another survivor Rob Purdie contracted fungal meningitis after he inhaled spores while gardening and now depends on lifelong toxic treatments. Aspergillus fumigatus , another dangerous fungus, could spread across Europe, Asia, and the Americas, and will affect millions of vulnerable individuals. This fungus, a study said, thrives in warm, damp environments and could potentially infect people by invading their lungs, particularly those who have underlying health issues like asthma, cystic fibrosis, or weakened immune systems.The World Health Organisation (WHO) reportedly has enlisted nearly 6.5 million invasive fungal infections. This, they said, results in 3.8 million deaths globally each year and the numbers are climbing due to increasing drug resistance.They listed 19 fungal species under urgent priorities for new drug development, among which Aspergillus fumigatus is one. Other dangerous species include Cryptococcus neoformans (deadly meningitis), Candida auris (highly drug-resistant hospital infections) and Candida albicans (common yeast that can become invasive).The CNN report stated that developing antifungal drugs is especially challenging since fungi are genetically closer to humans than bacteria. This means, the treatments can harm human cells, which could result in kidney failure, liver damage, or other severe side effects.Dr Neil Clancy, an infectious disease specialist and associate professor of medicine at University of Pittsburgh, told CNN that if an antifungal drug is being made, it is crucial to come up with formulations that will not harm genes and human proteins.Experts have noted that changing climate patterns, wildfires, and dust storms likely expand the fungi's geographic reach. Reportedly, cases of Coccidioides infection have been reported in over 20 US states, including regions which previously were unaffected.The study on Aspergillus fumigatus stated it could expand across an additional 77 per cent of global territory by 2100 as climate change is accelerated. Researchers have estimated that 9 million people in Europe alone could be exposed to infection risks if fungus takes hold.Reportedly, the fungus can grow rapidly in compost at high temperatures and can survive the human body's internal heat of 37°C. It was also found thriving in extreme environments like Chernobyl's nuclear reactors.Experimental drugs like Olorofim offer hope, however, experts have warned that limited specialist access and lack of public awareness could leave many patients untreated or misdiagnosed. More research, better treatments, and physician training are urgently needed to confront this growing fungal superbug threat, stated the CNN report.Professor Elaine Bignell, co-director at the MRC Centre for Medical Mycology at Exeter University, said that the development of new antifungal treatments has been slow. One key reason, as per an NDTV report, is financial unattractiveness of investing in antifungal medicines.Reportedly, the antifungal medicines are costly to develop and often spotted as less profitable compared to others in drug market.They are fungal infections that no longer react to usual antifungal treatment, so they are more difficult to treat and are possibly fatal.WHO includes species such as Aspergillus fumigatus, Candida auris, Cryptococcus neoformans, and Coccidioides among the most lethal ones.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

86.5 lakh deaths in 2022, 15 pc dip over Covid-hit 2021: CRS data
86.5 lakh deaths in 2022, 15 pc dip over Covid-hit 2021: CRS data

Hindustan Times

time30 minutes ago

  • Hindustan Times

86.5 lakh deaths in 2022, 15 pc dip over Covid-hit 2021: CRS data

New Delhi, Nearly 86.5 lakh deaths were reported in the country during 2022, a significant decline of more than 15 per cent from Covid-affected 2021 which had recorded over 1.02 crore deaths, according to a new data from the Civil Registration System . The dip of 15.74 lakh from 2021 brought mortality figures broadly back in line with pre-pandemic patterns last seen in 2020, the data for 2022 brought out by the office of the Registrar General of India through CRS report showed. According to the CRS data, 2021 registered a sharp spike with 1.02 crore deaths across the country as compared to 81.1 lakh in 2020, 76.4 lakh in 2019, and 69.5 lakh in 2018, underscoring the impact of COVID-19. "In the case of registered deaths, the number has decreased from 102.2 lakh in 2021 to 86.5 lakh in 2022, i.e. a decrease of 15.4 per cent. Some of the major states namely, Gujarat, Maharashtra, Madhya Pradesh, Andhra Pradesh, Tamil Nadu, Uttar Pradesh, Karnataka, West Bengal, Bihar and Haryana have contributed significantly to the decreased number of registered deaths," the report said. Around 5.26 lakh deaths were reported due to COVID-19 till July 26, 2022, according to a reply given by the government in the Lok Sabha on July 29, 2022. The World Health Organisation had reported over 47 lakh COVID-19 linked deaths in India which was strongly disputed by the government. The Centre had said the WHO estimates suffered from "a number of inconsistencies and erroneous assumptions". "India had registered a strong objection to the process, methodology and outcome of this unscientific modelling approach especially when India had provided authentic data published through Civil Registration System by Registrar General of India to WHO," the government reply had said. The CRS report also showed that over 2.54 crore births were registered in 2022. "The number of registered births has increased from 242.0 lakh in 2021 to 254.4 lakh in 2022,“ an increase of about 5.1 per cent," the report said. There has been an increase in 2022 in registered births in almost all states and UTs, except Bihar, Haryana, Himachal Pradesh, Sikkim, West Bengal, Ladakh, and Lakshadweep as compared to 2021. Nine major states namely, Uttar Pradesh, Madhya Pradesh, Maharashtra, Jharkhand, Karnataka, Gujarat, Telangana, Chhattisgarh and Assam have contributed significantly to the increase in registered births in 2022 over 2021, the report said. "On the other hand, decrease in registered births in six figures has been observed in two major states namely, West Bengal and Bihar during 2021-2022," it said.

Dr explains: Why booster shots are crucial even with mild Covid-19 symptoms prevailing
Dr explains: Why booster shots are crucial even with mild Covid-19 symptoms prevailing

First Post

timean hour ago

  • First Post

Dr explains: Why booster shots are crucial even with mild Covid-19 symptoms prevailing

India is experiencing a mild surge in COVID-19 cases driven by new Omicron subvariants, with mostly mild symptoms and low hospitalizations. Experts stress the importance of boosters, surveillance and protecting vulnerable groups. Firstpost brings out a doctor's view on symptoms, vaccine effectiveness, and the country's preparedness in tackling the evolving situation. read more According to the Ministry of Health and Family Welfare, India's active Covid-19 cases have reached 5,364 as of Friday, with Kerala remaining the most affected state, reporting over 1,600 active cases. Gujarat, West Bengal, and Delhi follow, with Delhi recording 592 active cases while conducting an average of 1,200 RT-PCR tests daily. The recent surge is primarily driven by newer Omicron subvariants. Firstpost talked to Dr. Diksha Goyal, Consultant – Internal Medicine, Marengo Asia Hospital, Gurugram to shed light on the current Covid-19 scenario, the impact of emerging variants and what people need to know. STORY CONTINUES BELOW THIS AD Reports indicate new variants like LF.7, XFG, JN.1, and NB.1.8.1 are driving the surge. Which of these are currently most prevalent in India? The JN.1 subvariant of Omicron is currently the most widespread in India. Other variants like LF.7, XFG, and NB.1.8.1 are present but less common. All appear to cause mild, self-limiting infections, with no significant rise in severe cases or hospitalisation. Are there any emerging symptoms that differ from previous Covid-19 waves? Yes, while traditional symptoms like fever and cough persist, new symptoms such as hoarseness, sore throat, fatigue, and mild gastrointestinal issues (like nausea or diarrhoea) are increasingly reported. These variants may feel milder but remain highly transmissible. How do current case and hospitalisation numbers compare to earlier waves? The current surge is far less severe than previous waves. Most infections are mild, and the healthcare system is not under strain. Authorities are maintaining readiness, but infrastructure and critical care services are coping well. How deadly are these new variants compared to earlier ones like Delta or previous Omicron strains? Clinically, the newer variants are more contagious but less lethal than the Delta variant. Symptoms are often milder than or similar to previous Omicron subvariants, particularly in vaccinated individuals. However, those at higher risk should remain cautious. The WHO has classified NB.1.8.1 as a 'Variant Under Monitoring.' What does this mean? This label signals genetic changes that could affect how the virus behaves, including its ability to spread or evade immunity. While not currently a major threat, it warrants close observation in case of any future risk. Are specific groups more vulnerable to severe illness with these new variants? Yes. Older adults, immunocompromised individuals, pregnant women, and children remain more susceptible to complications. Their immune systems may be weaker or still developing, so vaccination and preventive measures are essential. With waning immunity, what's your advice on booster doses? Booster shots are crucial, especially for high-risk people. They help sustain protection, reduce the severity of illness, and lower the chance of hospitalisation. Staying up to date with boosters remains a key preventive strategy. How effective are current vaccines against these variants? Do we need new formulations? Existing vaccines still offer strong protection against severe illness, hospitalisation, and death. While they may be less effective at preventing infection, they remain beneficial. Updated formulations targeting newer variants could enhance this protection further. What about people with 'hybrid immunity' from both vaccination and infection? Hybrid immunity offers stronger, more durable protection than either vaccination or infection alone. It significantly reduces the risk of severe illness. However, this immunity may wane over time, so periodic boosters are still recommended. How important is genomic surveillance? Is India prepared? Ongoing surveillance and sequencing are vital for tracking new variants and guiding public health responses. India has ramped up its genomic capabilities, but sustained funding, coordination, and vigilance are needed to remain prepared for future waves. Could Covid-19 become seasonal like the flu? That's a strong possibility. Covid-19 may eventually become endemic with periodic surges, much like influenza. The pattern will depend on factors such as mutations, immunity levels, and public health responses. What key lessons from past waves should guide future responses? The most important lessons are early detection, rapid response, and transparency. Strengthening healthcare infrastructure, ensuring vaccine access, and maintaining public health measures during surges are essential for staying ahead of the virus.

How basic precautions, timely care can help keep high-risk individuals safe amid COVID-19 surge
How basic precautions, timely care can help keep high-risk individuals safe amid COVID-19 surge

Indian Express

time4 hours ago

  • Indian Express

How basic precautions, timely care can help keep high-risk individuals safe amid COVID-19 surge

Amid rising COVID-19 cases and fatalities, experts have advised that high-risk groups, including those above 65 years and people with comorbidities, such as diabetes, chronic lung or kidney disease, and heart conditions, need to be extra careful. According to Dr Viny Kantroo, senior consultant, respiratory, critical care and sleep medicine, Indraprastha Apollo Hospitals, Delhi, COVID-appropriate behaviour is essential for such people. This includes wearing a mask in crowded places, while traveling, or if you have respiratory symptoms, maintaining hand hygiene, avoiding touching your face, controlling chronic conditions like diabetes to avoid complications, and practising respiratory etiquette — sneezing or coughing into a tissue or your elbow. India is witnessing a fresh uptick in coronavirus infections, with 4,866 active infections and seven recent deaths, including that of a five-month-old infant with cerebral palsy. While the surge deserves attention, medical experts emphasise that the current variants cause milder illness in most individuals. The key to navigating this phase lies in awareness, adherence to COVID-appropriate behaviour, and timely care for vulnerable groups, says Dr Kantroo. With around 28-30 patients currently hospitalised in Delhi, most admissions are precautionary or involve high-risk individuals. The majority of infections continue to be mild or moderate, and the healthcare system is well-prepared to handle such cases. For those who test positive and have high-risk conditions, doctors may prescribe antiviral treatment like Paxlovid, ideally within five days of the onset of symptoms and after checking liver and kidney function. High-risk groups remain most vulnerable to complications. You should be more vigilant if you fall in the following categories: • Senior citizens (65+ years) • Diabetics and those with heart, lung, kidney, or liver disease • Immunocompromised individuals, including cancer and transplant patients and those on steroids or immunosuppressants • Pregnant women with comorbidities • People with a history of severe COVID infection Seek early medical care if you experience: • Shortness of breath • Low oxygen saturation • Persistent symptoms beyond seven days • A fever that is not responding to treatment As of now, booster vaccines are not recommended for the general population in India. There are no updated COVID-19 boosters available locally, and authorities like the World Health Organization (WHO) are still assessing the evolving behaviour of the virus. However, high-risk individuals should consult their physicians regarding preventive care, the focus should remain on overall health, masking, and early detection. The current surge is driven by new Omicron sub-variants such as JN.1, NB.1.8.1, LF.7, and XFC, which have shown increased transmissibility but mostly mild symptoms. The WHO currently classifies these as 'Variants Under Monitoring' — not of concern yet, but requiring caution. These viruses are known for their ability to mutate, similar to influenza, which is why vigilance and seasonal updates remain relevant. The current COVID-19 phase does not warrant panic, says Dr Kantroo, but calls for caution, preparedness, and responsible behaviour. Following basic health measures, staying updated, and seeking timely care can go a long way in keeping ourselves and our communities safe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store